Evogene targets acute graft-versus-host disease in AI-driven drug discovery program
EVGN•Evogene announced acute graft-versus-host disease as the target of its internal AI-driven drug discovery program, focusing on patients unresponsive to steroids. Lead candidates are advancing toward studies supporting an investigational new drug application; the disease affects about 30%-40% of stem cell transplant recipients, and mortality among steroid-refractory patients can reach 50%.
1. Program targets disease
Evogene said its AI-driven drug discovery program will target acute graft-versus-host disease in patients unresponsive to steroids. Discovery-stage findings showed promising potency, selectivity and safety-related profiles, and lead candidates are advancing toward studies supporting an investigational new drug application. The company described the market as potentially multibillion-dollar and said ruxolitinib remains the only approved second-line therapy.
